Keywords: Probes & Targets, MR-Guided Interventions, Glioblastoma, Mesenchymal stem cells
Motivation: Immunotherapy resistance in glioblastoma (GBM) has been linked to a paucity of tumor-infiltrating T lymphocytes and concurrent T-cell dysfunction.
Goal(s): This research aims to determine whether MRI-visible mesenchymal stem cells (MSCs) could be employed for GBM immunotherapy.
Approach: CXCL10-Nrf2-FTH-MSCs with enhanced T lymphocyte recruitment (Cxcl10 gene), oxidative stress tolerance (Nrf2 gene), and MRI visibility (Fth gene) were genetically engineered. With the guidance of FTH-MRI, these MSCs were injected into the tumor periphery of orthotopic GL261 GBMs in mice.
Results: In vivo MRI monitoring and histology examinations demonstrated that CXCL10-Nrf2-FTH-MSCs can significantly limit GBM growth by reviving T lymphocytes within the tumor.
Impact: FTH-MRI is a practical method for guiding intracranial stem cell transplantation. MRI-guided peritumoral implantation of CXCL10-Nrf2-FTH-MSCs provides a novel immunotherapeutic approach based on tumoricidal stem cells for the treatment of GBM.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords